Rowan Chapman
Partner @ Mohr Davidow Ventures
San Francisco, United States
Rowan Chapman is a seed investor at Mohr Davidow Ventures in San Francisco focused on Genetics and Analytics. Rowan Chapman is the Co-Founder of Initiate and Chief Business Officer at Dynamics Special Purpose Corporation. He attended the University of California, San Francisco.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Rowan Chapman invests in
Stages Rowan Chapman invests in
Countries Rowan Chapman invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Genetics 1 (20%)
- Analytics 1 (20%)
- Health Care 1 (20%)
- Biotechnology 1 (20%)
- Health Diagnostics 1 (20%)
Stage
- Seed 1 (20%)
- Series A 1 (20%)
- Series B 1 (20%)
- Series C 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Cornerstone AI provides the cleaning and standardizing of data and too analyzing it. each had built internal tooling to take steps to improve this process. | $5M / Seed / Oct 30, 2024 | ||
| Cornerstone AI provides the cleaning and standardizing of data and too analyzing it. each had built internal tooling to take steps to improve this process. | $5M / Seed / Jul 18, 2022 | ||
| Personalis combines both the technology of sequencing and interpretation, with an extensive history of peer-reviewed publication and commercial success. It is providing an extensive molecular view of a patient’s tumor and characterizes its interplay with the immune system. It aids in the development of safer, effective precision cancer therapies,immunotherapies, and personalized medicines. | $33M / Series C / Jan 13, 2015 | ||
| Personalis combines both the technology of sequencing and interpretation, with an extensive history of peer-reviewed publication and commercial success. It is providing an extensive molecular view of a patient’s tumor and characterizes its interplay with the immune system. It aids in the development of safer, effective precision cancer therapies,immunotherapies, and personalized medicines. | Series B / Oct 07, 2013 | ||
| Personalis combines both the technology of sequencing and interpretation, with an extensive history of peer-reviewed publication and commercial success. It is providing an extensive molecular view of a patient’s tumor and characterizes its interplay with the immune system. It aids in the development of safer, effective precision cancer therapies,immunotherapies, and personalized medicines. | Series A / Aug 15, 2011 |
Co-Investors
About Mohr Davidow Ventures
For 30 years the _Mohr Davidow Ventures team has invested in early stage technology-based startups that redefine or create large new markets. They believe that emerging information technology innovations are enabling a decade-long opportunity to invest in the “Era of Digital Engagement,” one in which personal, commercial, and public sectorinteractions of all kinds will be profoundly reengineered to leverage the power of mobile devices, cloud computing, and data analytics. The Firm seeks to identify and partner with exceptional entrepreneurs who leverage these technologies to build companies where seamless, deep engagement with customers will create billion dollar markets in a number of different verticals. These verticals include: Digital Marketing, Advertising, & Media, Collaborative Enterprise Applications, The Digitization of Education and Health, Digital Financial Services, E‐commerce & Digital Retail Innovation, Mobile/Web‐Powered “LifeTech.” The Firm also has previous investments in the innovative life sciences & genomics space.Leading companies funded by Mohr Davidow Ventures includes: Agile (Acquired by NYSE: ORCL); Aryaka Networks; Brocade; Coupa; Genomatica; HealthTap; Infusionsoft; Kabbage; nLight; ONI Systems (Acquired by NASDAQ: CIEN); Proofpoint (NASDAQ: PFPT); Rally Software (NYSE: RALY); Rocket Fuel (NASDAQ: FUEL); Rambus; Shutterfly (NASDAQ: SFLY); Ticketfly; Verinata Health (Acquired by NASDAQ: ILMN); and Visible Measures. The Firm has $1.85 billion under management.
Mohr Davidow Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Randy Strahan
Venture Partner
|
|||
Bill Davidow
Partner Emeritus
|
|||
Bill Ericson
General Partner
|
|||
Bryan Stolle
General Partner
|
|||
Erik Straser
General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Rowan Chapman invest in?
Rowan Chapman invests primarily in Genetics, Analytics and Health Care startups, most often at Seed and Series A stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Rowan Chapman?
Public channels for Rowan Chapman include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Rowan Chapman last invest?
The most recent investment recorded for Rowan Chapman closed in Oct 2024. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
